Literature DB >> 27664149

reply to the letter to the editor 'Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trial' by Ceccarelli et al.

M E Lacouture1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27664149      PMCID： PMC5091323          DOI： 10.1093/annonc/mdw403

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  2 in total

1.  Reply to the letter to the editor 'Utilisation of the ESMO-MCBS in practice of HTA' by Wild et al.

Authors:  N I Cherny; R Sullivan; U Dafni; J Bogaerts; J M Kerst; C Zielinski; M J Piccart; E G E de Vries
Journal:  Ann Oncol       Date:  2016-08-29       Impact factor: 32.976

2.  A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer.

Authors:  M E Lacouture; D M Keefe; S Sonis; A Jatoi; D Gernhardt; T Wang; J P Doherty; N Giri; S Nadanaciva; J O'Connell; E Sbar; B Piperdi; E B Garon
Journal:  Ann Oncol       Date:  2016-06-10       Impact factor: 32.976
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.